Venus Remedies share news, announcements and annual reports
NSE: VENUSREMBSE: 526953Pharmaceuticals & BiotechnologySmall Cap
Venus Remedies Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed May 1995 on BSE, Dec 2006 on NSE
Last close ₹1,238.60down ₹50.70 (3.93%)BSE ₹1,231.75
Share price at the NSE close on 30 Oct 2026. Previous close ₹1,289.30.
30 Oct: open ₹1,290.00, high ₹1,319.00, low ₹1,225.10
52-week range of traded prices to 30 Oct 2026
₹432.10Low, 31 Oct 2025₹2,044.30High, 29 Jun 2026
- Under NSE's long-term additional surveillance, stage IV, on the list for 30 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Delivery only: shares bought must be paid for in full, with no selling on the same day.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹1,656 Cr1,337th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 13.61
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.35
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.81%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 18.7%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 21.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day. Volume in the glossary
- 48,127
Venus Remedies share news and announcements
697 announcements, routine notices left out, newest first. Page 9 of 14.
Apr 2017
13 Apr · Legal
Exchange has sought clarification from Venus Remedies Limited with respect to announcement dated 13-Apr-2017, regarding the Board of Directors of the Company in its meeting held on April 13, 2017 have appointed M/s Prem Garg & Associates, Chartered Accountants as statutory auditors of the Company as per section 139 of the Companies Act, 2013, w.e.f. April 1, 2017 subject to approval in shareholders' meeting. On basis of above the Company is required to clarify following: 1. Brief profile (in case of appointment);The response of the Company is awaited.
Mar 2017
22 Mar · Meeting
Feb 2017
8 Feb · Board meeting
His is to inform you that, the Board of Directors of the Company at its meeting held February 08, 2017 has allotted 9,00,000 warrants fully convertible into equity shares to promoters on preferential basis.8 Feb · Results
Jan 2017
Nov 2016
9 Nov · Results
Oct 2016
18 Oct · Updates
1 Oct · Regulation 44(3) of SEBI (LODR), Reg., 2015
Sep 2016
Aug 2016
Jul 2016
26 Jul · Audit Qualifications/Comments
Jun 2016
May 2016
Apr 2016
Feb 2016
2 Feb · Board meeting
To inter alia consider and approve Unaudited Financial Results (Provisional) for the quarter ended December 31, 2015 and any other item with the permission of chair.
Dec 2015
Nov 2015
2 Nov · Board meeting
To inter alia consider and approve Unaudited Financial Results (Provisional) for the quarter ended September 30, 2015, to reconsider the relevant date for the preferential issue approved by the shareholders in AGM dated August 25, 2015 and any other item with the permission of chair.
Aug 2015
4 Aug · Meeting
Register of Members and Share Transfer Books shall remain closed from August 20, 2015 to August 25, 2015 (both days inclusive) for the purpose of Annual General Meeting proposed to be held on August 25, 2015.4 Aug · Updates
Of E-voting shall be activated from August 20, 2015 to August 22, 2015 from at 9:00 am to 5:00 pm., as per the procedure mentioned in the AGM notice.